Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYP001a in chronic hepatitis B
NL-OMON46529Phase 1Active, not recruiting
- Sponsor
- ENYO Pharma
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of vonafexor in Chronic Hepatitis B (CHB) (9 arms), sponsored by ENYO Pharma. Primary endpoints: Safety and tolerability and Pharmacokinetics of EYP001a. Started Sep 2017; status: active, not recruiting.
02
Drugs
vonafexor
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NL-OMON46529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46529.